Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction.
Psaty
Bruce M
BM
Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA 98177, USA. psaty@u.washington.edu
Siscovick
David S
DS
D000959:Antihypertensive Agents / Q000627:therapeutic use; D015982:Bias; D002318:Cardiovascular Diseases / Q000150:complications; D057186:Comparative Effectiveness Research / Q000706:statistics & numerical data*; D015986:Confounding Factors, Epidemiologic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000517:prevention & control; D019370:Observation; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results
D000959:Antihypertensive Agents; D007004:Hypoglycemic Agents